Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The company is also involved in immune system research related to autoimmune diseases. It employs about 2,400 people worldwide. On February 29, 2016, the company held the dedication ceremony for its brand-new headquarters in New Haven, CT, not far from the companys starting point in the same city.
Highest paying job titles at Alexion Pharmaceuticals include Field Reimbursement Manager, Regional Account Manager, and Director of Life Sciences